Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors

Affiliations

• ¹ Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio Hospital, Sevilla, Spain; Centro de investigación biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: [email protected].
• ² Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio Hospital, Sevilla, Spain.
• ³ Fondazione IRCCS Policlinico San Matteo, Department of Internal Medicine, University of Pavia, Pavia, Italy; Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
• ⁴ Nephrology Unit, Virgen del Rocio Hospital, Sevilla, Spain.
• ⁵ Department of Nephrology, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
• ⁶ Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
• ⁷ Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.